These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors]. Jahnz-Rozyk K; Wiesik-Szewczyk E; Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192 [TBL] [Abstract][Full Text] [Related]
10. [Biosimilars in the European Union: current situation and challenges]. Wolff-Holz E; Weise M Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1365-1372. PubMed ID: 33034693 [TBL] [Abstract][Full Text] [Related]
11. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Yoo DH Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712 [TBL] [Abstract][Full Text] [Related]
13. Regulatory considerations in oncologic biosimilar drug development. Macdonald JC; Hartman H; Jacobs IA MAbs; 2015; 7(4):653-61. PubMed ID: 25961747 [TBL] [Abstract][Full Text] [Related]
14. Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals. Pawłowska I; Pawłowski L; Krzyżaniak N; Kocić I BioDrugs; 2019 Apr; 33(2):183-191. PubMed ID: 30830647 [TBL] [Abstract][Full Text] [Related]
15. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference. Crespi-Lofton J; Skelton JB J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708 [TBL] [Abstract][Full Text] [Related]
16. Antibody biosimilars: fears or opportunities?: First LabEx MAbImprove industrial workshop, May 28, 2013; Tours, France. Guillon-Munos A; Daguet A; Watier H MAbs; 2014; 6(4):805-9. PubMed ID: 24714167 [TBL] [Abstract][Full Text] [Related]
17. Biosimilars: Practical Considerations for Pharmacists. Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529 [TBL] [Abstract][Full Text] [Related]
18. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe. Müller-Ladner U; Hong S; Oh C; Taylor P Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832 [TBL] [Abstract][Full Text] [Related]
19. Biosimilars in the therapy of inflammatory bowel diseases. Hlavaty T; Letkovsky J Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561 [TBL] [Abstract][Full Text] [Related]
20. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Braun J; Kudrin A Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]